Low-dose rivaroxaban reduces risk in PAD post-revascularization

In the VOYAGER PAD trial, patients with symptomatic peripheral artery disease who underwent lower-extremity revascularization had a lower incidence of major adverse limb and CV events compared if treated with low-dose rivaroxaban twice daily plus aspirin, compared with aspirin only.